Patents by Inventor Charles F. Schwender

Charles F. Schwender has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020151553
    Abstract: Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation.
    Type: Application
    Filed: October 2, 2001
    Publication date: October 17, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Charles F. Schwender, Charles R. Mackay, Julia C. Pinto, Walter Newman
  • Patent number: 6458806
    Abstract: Aryl alkenamides derivatives of Formula I or a pharmaceutically acceptable salt thereof are novel MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection where V═O,S, NH or a bond; Ar can be unsubstituted or substituted benzimidazole, phenyl, biphenyl, pyridyl, naphthyl, quinoline or isoquinoline. The other meanings for the terms are recited in the specification below.
    Type: Grant
    Filed: August 12, 1997
    Date of Patent: October 1, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Richard John Booth, Kenneth Gordon Carson, David Thomas Connor, Roberta Ellen Glynn, Bruce David Roth, Charles F. Schwender, Bharat Kalidas Trivedi, Paul Charles Unangst
  • Publication number: 20020103111
    Abstract: The present invention provides novel compounds comprising peptide sequences which mimic the conserved amino acid motif LDTSL of MAdCAM-1 and which have groups bonded to the N- and C-termini. Also provided are methods of inhibiting the interaction of a cell bearing a ligand of MAdCAM-1, such as human &agr;4&bgr;7, with MAdCAM-1 or a portion thereof (e.g., the extracellular domain), comprising contacting the cell with a compound of the present invention.
    Type: Application
    Filed: May 16, 2001
    Publication date: August 1, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Charles F. Schwender, Hitesh N. Shroff
  • Publication number: 20020028833
    Abstract: Aryl alkenamides derivatives of Formula I or a pharmaceutically acceptable salt thereof are novel MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection 1
    Type: Application
    Filed: August 12, 1997
    Publication date: March 7, 2002
    Inventors: RICHARD JOHN BOOTH, KENNETH GORDON CARSON, DAVID THOMAS CONNOR, ROBERTA ELLEN GLYNN, BRUCE DAVID ROTH, CHARLES F. SCHWENDER, BHARAT KALIDAS TRIVEDI, PAUL CHARLES UNANGST
  • Patent number: 6323206
    Abstract: Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to the subject a therapeutically effective amount of a compound represented by the following structural formula: and physiologically acceptable salts thereof.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: November 27, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Charles F. Schwender, Charles R. Mackay, Julia C. Pinto, Walter Newman
  • Patent number: 6281212
    Abstract: Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to the subject a therapeutically effective amount of a compound represented by the following structural formula: and physiologically acceptable salts thereof. Z is a substituted or unsubstitured aromatic group. Y is a covalent bond, —O— or —CO—. n is an integer from one to about five. X is a covalent bond or —CO—. Ra is an aliphatic or a substituted aliphatic group; Rb is an aliphatic group substituted with an aromatic group or substituted aromatic group; and, taken together with the nitrogen atom bonded to Ra and Rb, can form a substituted or unsubstituted non-aromatic heterocyclic ring.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: August 28, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Charles F. Schwender, Charles R. Mackay, Julia C. Pinto, Walter Newman
  • Patent number: 6274556
    Abstract: The present invention provides novel compounds comprising peptide sequences which mimic the conserved amino acid motif LDTSL of MAdCAM-1 and which have groups bonded to the N- and C-termini. Also provided are methods of inhibiting the interaction of a cell bearing a ligand of MAdCAM-1, such as human &agr;4&bgr;7, with MAdCAM-1 or a portion thereof (e.g., the extracellular domain), comprising contacting the cell with a compound of the present invention.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: August 14, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Charles F. Schwender, Hitesh N. Shroff
  • Patent number: 6037324
    Abstract: The present invention provides novel compounds comprising peptide sequences which mimic the conserved amino acid motif LDTSL and which have groups bonded to the N- and C-termini. Also provided are methods of inhibiting the interaction of a cell bearing a ligand of MAdCAM-1, such as human .alpha.4.beta.7, with MAdCAM-1 or a portion thereof (e.g., the extracellular domain), comprising contacting the cell with a compound of the present invention.
    Type: Grant
    Filed: January 4, 1996
    Date of Patent: March 14, 2000
    Assignee: LeukoSite, Inc.
    Inventors: Charles F. Schwender, Hitesh N. Shroff
  • Patent number: 5834521
    Abstract: Tetracyclic compounds having the following structure are described: ##STR1## wherein R.sub.1 -R.sub.10 are as defined. The tetracyclic compounds are capable of potent effects on steroid sensitive tissues and have demonstrated increased uterine weight, antiovulatory effects and potent steroid receptor binding. The compounds have therapeutic utility in reproductive applications such as fertility control, labor induction, ovulation induction and spermatogenesis. Methods for preparing the tetracyclic compounds from substituted indanones are also described.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: November 10, 1998
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: John H. Dodd, Lisa A. Dixon, James L. Bullington, Charles F. Schwender
  • Patent number: 5508419
    Abstract: This invention relates to novel bis-biphenyl substituted 3-mercapto-1,2,4-tetrazoles and to pharmaceutically acceptable salts thereof.The compounds are angiotensin II receptor antagonists, and are useful in treating hypertension (lowering high blood pressure), congestive heart failure, elevated ocular pressure, cerebral stroke, angina, cardiac insufficiency, myocardial infarction or diabetic nephropathy.The invention also relates to a pharmaceutical composition comprising a compound of the invention, a method of treating a physiological condition in a mammal that is mediated by angiotensin II which comprises administering to the mammal an effective amount of a compound of the invention, and novel processes for preparing the compounds of the invention.
    Type: Grant
    Filed: September 9, 1994
    Date of Patent: April 16, 1996
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Victor T. Bandurco, William V. Murray, Michael P. Wachter, Charles F. Schwender
  • Patent number: 5347011
    Abstract: This invention relates to novel bis-biphenyl substituted 3-mercapto-1,2,4-tetrazoles and to pharmaceutically acceptable salts thereof.The compounds are angiotensin II receptor antagonists, and are useful in treating hypertension (lowering high blood pressure), congestive heart failure, elevated ocular pressure, cerebral stroke, angina, cardiac insufficiency, myocardial infarction or diabetic nephropathy.The invention also relates to a pharmaceutical composition comprising a compound of the invention, a method of treating a physiological condition in a mammal that is mediated by angiotensin II which comprises administering to the mammal an effective amount of a compound of the invention, and novel processes for preparing the compounds of the invention.
    Type: Grant
    Filed: June 7, 1993
    Date of Patent: September 13, 1994
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Victor T. Bandurco, William V. Murray, Michael P. Wachter, Charles F. Schwender
  • Patent number: 5240953
    Abstract: This invention relates to novel bis-biphenyl substituted 3-mercapto-1,2,4-tetrazoles and to pharmaceutically acceptable salts thereof.The compounds are angiotensin II receptor antagonists, and are useful in treating hypertension (lowering high blood pressure), congestive heart failure, elevated ocular pressure, cerebral stroke, angina, cardiac insufficiency, myocardial infection or diabetic nephropathy.The invention also relates to pharmaceutical composition comprising a compound of the invention, a method of treating a physiological condition in a mammal that is mediated by angiotensin II which comprises administering to the mammal an effective amount of a compound of the invention, and novel processes for preparing the compounds of the invention.
    Type: Grant
    Filed: January 30, 1992
    Date of Patent: August 31, 1993
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Victor T. Bandurco, William V. Murray, Michael P. Wachter, Charles F. Schwender
  • Patent number: 5075440
    Abstract: Novel pyrido[2,3-f] [1,4]thiazepines and novel pyrido[3,2-b] [1,5]benzothiazepines of the formula: ##STR1## These compounds are useful as calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstriction activity. Also described are methods of producing the novel compounds and intermediates thereof.
    Type: Grant
    Filed: May 3, 1990
    Date of Patent: December 24, 1991
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: David J. Wustrow, Charles F. Schwender, John H. Dodd
  • Patent number: 4939133
    Abstract: The present invention relates to novel N-substituted 2-hydroxybenzamide and N-substituted 2-hydroxy-.alpha.-oxo-benezene acetamide compounds pharmaceutical compositions, and methods of use for therefore for the treatment of diseases in which products having lipoxygenase enzyme activity contribute to the pathological condition. Selected novel intermediates are also the present invention.
    Type: Grant
    Filed: October 1, 1985
    Date of Patent: July 3, 1990
    Assignee: Warner-Lambert Company
    Inventors: David T. Connor, Daniel L. Flynn, Wiaczeslaw A. Cetenko, Jagadish C. Sircar, Charles F. Schwender, Elizabeth A. Johnson, Roderick J. Sorenson, Paul C. Unangst
  • Patent number: 4921871
    Abstract: The present invention relates to novel enolamide type compounds, pharmaceutical compositions, and methods of use thereof, useful in the treatment of diseases in which products of lipoxygenase enzyme activity or the action of leukotrienes contribute to the pathological condition.
    Type: Grant
    Filed: November 16, 1987
    Date of Patent: May 1, 1990
    Assignee: Warner-Lambert Company
    Inventors: Mary E. Carethers, Wiaczeslaw A. Cetenko, David T. Connor, Elizabeth A. Johnson, John S. Kiely, Charles F. Schwender, Jagadish C. Sircar, Roderick J. Sorenson, Paul C. Unangst, Robert F. Bruns
  • Patent number: 4921859
    Abstract: Novel purine derivatives are described as agents for treating autoimmune diseases as well as a method of manufacture and pharmaceutical compositions as well as novel intermediates in the manufacture thereof.
    Type: Grant
    Filed: September 29, 1988
    Date of Patent: May 1, 1990
    Assignee: Warner-Lambert Company
    Inventors: Jagadish C. Sircar, Charles F. Schwender, Mark J. Suto
  • Patent number: 4918219
    Abstract: Novel purine derivatives are described as agents for treating autoimmune diseases as well as a method of manufacture and pharmaceutical compositions as well as novel intermediates in the manufacture thereof.
    Type: Grant
    Filed: September 29, 1989
    Date of Patent: April 17, 1990
    Assignee: Warner-Lambert Company
    Inventors: Jagadish C. Sircar, Charles F. Schwender, Mark J. Suto
  • Patent number: 4879384
    Abstract: Novel substituted thiacycloalkeno [3,2-b] pyridines are described. These compounds are useful as calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstrictor activity.
    Type: Grant
    Filed: June 15, 1988
    Date of Patent: November 7, 1989
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Charles F. Schwender, John H. Dodd
  • Patent number: 4874862
    Abstract: Novel guanine derivatives are described as agents for treating autoimmune diseases as well as a method of manufacture and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 14, 1987
    Date of Patent: October 17, 1989
    Assignee: Warner-Lambert Company
    Inventors: Jagadish C. Sircar, Catherine R. Brungardt, Charles F. Schwender
  • Patent number: 4874758
    Abstract: The present invention relates to novel enolamide type compounds, pharmaceutical compositions, and method of use thereof, useful in the treatment of diseases in which products of lipoxygenase enzyme activity or the action of leukotrienes contribute to the pathological condition.
    Type: Grant
    Filed: March 4, 1988
    Date of Patent: October 17, 1989
    Assignee: Warner-Lambert Company
    Inventors: Mary E. Carethers, Wiaczeslaw A. Centenko, David T. Connor, Elizabeth A. Johnson, John S. Kiely, Charles F. Schwender, Jagadish C. Sircar, Roderick J. Sorenson, Paul C. Unangst, Robert F. Bruns